Medical Information
Afrique
 

This medical information website is intended only for healthcare professionals in Africa. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

I am a healthcare professional registered to practice in AfricaYes, I am a healthcare professional
SelectI am a healthcare professional registered to practice in AfricaYes, I am a healthcare professional
I am not a Healthcare ProfessionalNo, go back to the patient portal
SelectI am not a Healthcare ProfessionalNo, go back to the patient portal
Where do you work / live?
SubmitSubmit
I am a Healthcare Professional in another country.

Congress Materials

The information on this page pertains to selected congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.

Oral Presentation
Grivas P, Bellmunt J, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Loriot Y, Sridhar SS, Tsuchiya N, Sternberg CN, Aragon-Ching JB, Petrylak DP, Blake-Haskins JA, Laliberte RJ, Wang J, Costa N, Powles T May 13, 2022 AUA 2022 Urothelial Cancer

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Follow-Up Results From the JAVELIN Bladder 100 Trial

View Presentation View Abstract Plain Language Summary
Poster
Kopenhafer L, Chang J, Thompson A, Sikirica S, Masters ET, Cappelleri JC, Peck EY, Maculaitis MC May 18, 2022 ISPOR 2022 Urothelial Cancer

The Burden of High-Risk Non-Muscle Invasive Bladder Cancer Among Patients Treated With Bacillus Calmette-Guérin

View Presentation
Poster
Milloy N, Kirker M, Berry M, Montgomery R, Bleasdale C, Kearney M, Costa N, Chang J May 18, 2022 ISPOR 2022 Urothelial Cancer

Treatment Patterns in Metastatic Urothelial Cancer (mUC): A Real-World Survey in France, Germany, Italy, Spain, and the UK (Eu5)

View Presentation
Poster
Shore N, Powles TB, Bedke J, Galsky MD, Kopyltsov E, Necchi A, Palou Redorta J, Vermette JJ, Randall AE, Pierce KJ, Cesari R, Steinberg GD June 4, 2022 ASCO 2022 Urothelial Cancer

A Phase 3 Study of the Subcutaneous Programmed Cell Death Protein 1 Inhibitor Sasanlimab as Single Agent for Patients with Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer: CREST Study Cohort B 

View Presentation View Abstract Plain Language Summary
Poster
Valderrama BP, Powles T, Sridhar SS, Caserta C, Loriot Y, Gupta S, Bellmunt J, Sternberg CN, Wang J, Costa N, Laliberte RJ, di Pietro A, Park SH, Grivas P June 4, 2022 ASCO 2022 Urothelial Cancer

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes From JAVELIN Bladder 100 in Subgroups Defined by Response to First-Line Chemotherapy

View Presentation View Abstract Plain Language Summary
Poster
Liu FX, Costantino H, Ike C, Gupta S, Bhanegaonkar A, Thakkar S, Devgan G, Katzenstein H June 4, 2022 ASCO 2022 Urothelial Cancer

Evaluating Oncologists’ Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): The US Physician PARADIGM Study (part 2)

View Presentation
Poster
Bellmunt J, Powles T, Climent Duran MA, Sridhar SS, Gurney H, Costa N, di Pietro A, Huang B, Gupta S, Grivas P June 4, 2022 ASCO 2022 Urothelial Cancer

Long-Term Outcomes in Patients With Advanced Urothelial Carcinoma who Received Avelumab First-Line Maintenance With or Without Second-Line Treatment: Exploratory Analyses From JAVELIN Bladder 100

View Presentation View Abstract Plain Language Summary
Oral Presentation
Powles T, Sridhar SS, Bellmunt J, Sternberg CN, Grivas P, Hunter E, Dezfouli M, Salter M, Powel R, Ding A, Green J, Akoulitchev A, Amezquita R, Ching K, Pu J, Deng S, di Pietro A, Davis CB September 10, 2022 ESMO 2022 Urothelial Cancer

Genomic Biomarkers in Peripheral Blood (PB) From Patients (Pts) Enrolled in the JAVELIN Bladder 100 Trial of Avelumab First-Line (1L) Maintenance in Advanced Urothelial Carcinoma (aUC)

View Presentation
Poster
Aragon-Ching JB, Grivas P, Loriot Y, Bellmunt J, Wang J, Michelon E, di Pietro A, Powles T, Sridhar SS September 12, 2022 ESMO 2022 Urothelial Cancer

Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From Patients With ≥12 Months of Treatment in JAVELIN Bladder 100

View Presentation View Abstract Plain Language Summary
Poster
Lapuente M, Milloy N, Berry M, Montgomery R, Bleasdale C, Kluth C, Kirker M, Kearney M, Costa N, Chang J September 12, 2022 ESMO 2022 Urothelial Cancer

Evaluating Real-World Caregiver Involvement From a Survey of Patients With Metastatic Urothelial Cancer (mUC) Receiving Systemic Anticancer Treatment in France, Germany, Italy, Spain, and the UK (Eu5)

View Presentation